Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
News
ASX January winners: The best 50 stocks as ASX S&P reaches record high
Health & Biotech
ASX Health Winners January: ‘Invest in business not science’, as SHG and PAA top winners list
News
In Case You Missed It: Project expansions, mineral resources and boardroom appointments ahoy!
Health & Biotech
PharmAust gets ethics committee green light for open-label MND extension study
News
Market Highlights: ‘They could cut rates 15 times’… and 5 ASX small caps to watch
News
In Case You Missed It: Key approvals for resource plays and Aroa looks to improve mastectomy surgery
Health & Biotech
ASX Health Stocks: Starpharma says Viraleze reduces viral load in nose, effective in Covid-19
Health & Biotech
FDA offers PharmAust clear guidance for orphan drug designation approval
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Small Caps Lunch Wrap: Who chain-smoked their way through a Chinese marathon last week?
Health & Biotech
The next Neuren? These ASX biotech stocks have pending FDA catalysts in 2024
Health & Biotech
PharmAust partners with US-based Berry Consultants for Phase 2/3 study
News
In Case You Missed It: Gold, uranium and a sudden leadership spill are driving the news today
Health & Biotech
ASX Health Stocks: Immuron chalks up record half for travelers’ diarrhoea medicine, Travelan
News
In Case You Missed It: Lithium, chocolate and an IVF tech distribution deal
Health & Biotech
PharmAust just got a pre-IND meeting with the US FDA to kick off ‘24
News
